From alchemy to IPO : the business of biotechnology

By Cynthia Robbins-Roth. 2000

114 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

From the gene to the globe: Extracting rents based on intellectual property monopolies (2007, background): “Xoma, which had sold the property rights on royalties, was left empty-handed, apart from the above-mentioned 17 million USD (Robbins-Roth, 2000: 159, 216; Xoma, 1998).”
The Performance of Incumbent firms in the Face of Radical Technological Innovation (2003, background): “For example, FDA regulations regarding preclinical testing, clinical trials, and product and process approval imply that the gestation period for developing new products based on biotechnology can exceed a decade (Robbins-Roth, 2000).”